Efficient diagnosis of Sjögren's syndrome to reduce the burden on patients

Niikura, Asumi J; Yamachika, Shigeo; Yamamoto, Ken; Okamoto, Mariko; Ikeda, Yoichi; Nakamura, S.; Oda, Etsuko; Imamura, Takahiro; Nakagawa, Yoichi

doi:10.3109/14397595.2014.927969

Cited by 3 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the high specificity was found in 2002 AECG criteria (92.19%) and 2012 ACR criteria (95.31%) to classify SS patients, however, the unsatisfactory sensitivity was also showed for 2002 AECG criteria (53.69%) and 2012 ACR criteria (59.06%). Similar results can be in other studies [ 2 , 10 , 11 , 17 ]. The new point-scoring diagnostic system was able to significantly improve the sensitivity for the diagnosis of SS while maintain a high specificity ( Table 4 ).…”

Section: Discussionsupporting

confidence: 92%

“…In this study, 41.31% patients with suspicious SS had not performed minor salivary glands biopsy. A qualitative SSG was mentioned in the 2002 AECG criteria, but it has been complained of low specificity and radiation exposure although it has high sensitivity [ 2 , 4 , 11 , 17 ]. In fact, radionuclide imaging of salivary gland yield only relatively low effective radiation doses compared with computed tomography (CT) for sialography [ 19 , 20 , 21 , 22 ], and has been increasingly accepted by clinicians and patients for it is noninvasive, convenient, and reasonably priced.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Point-Scoring System for the Clinical Diagnosis of Sjögren's Syndrome Based on Quantified SPECT Imaging of Salivary Gland

et al. 2016

View full text Add to dashboard Cite

ObjectiveTo establish a point-scoring diagnostic system for Sjögren's syndrome (SS) based on quantified SPECT imaging of salivary gland, and evaluate its feasibility and performance compared with 2002 AECG criteria and 2012 ACR criteria.Methods213 patients with suspected SS enrolled in this study. The related clinical data of all patients were collected. All patients were evaluated and grouped on a clinical basis and posttreatment follow-up by rheumatology specialists as the unified standard (SS group with 149 cases and nSS group with 64 cases). From SPECT imaging of salivary gland, Tmax, UImax, Ts and EFs were derived for bilateral parotid and submandibular glands, and compared between the groups. A point-scoring diagnostic system for SS was established based on the quantified SPECT imaging of salivary gland. We estimated the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy for the new diagnostic system, compared with 2002 AECG criteria and 2012 ACR criteria.ResultsWhen 7.0 was used as the cut-off point, the sensitivity, specificity, PPV, NPV and accuracy for the new point-scoring system in diagnosing SS were 89.93% (134/149), 93.75% (60/64), 97.10% (134/138), 80.00% (60/75) and 91.08% (194/213), respectively. The new point-scoring diagnostic system based on quantified SPECT imaging of salivary gland keeps the specificity comparatively to 2002 AECG criteria and 2012 ACR criteria, but improves the sensitivity significantly (P<0.01).ConclusionThe new point-scoring diagnostic system for SS based on quantified SPECT imaging of salivary gland may be superior to 2002 AECG criteria and 2012 ACR criteria, with higher sensitivity and similar specificity in the diagnosis of SS. Additionally, it also has good feasibility in the clinical settings.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

A Point-Scoring System for the Clinical Diagnosis of Sjögren's Syndrome Based on Quantified SPECT Imaging of Salivary Gland

et al. 2016

View full text Add to dashboard Cite

show abstract

“…As SS-specific biomarkers are unavailable to date, SS diagnosis requires the measurement of multiple clinical parameters, including less invasive blood tests to invasive MSGBx (25). The pathological role of anti-Ro/SSA in hyposalivation is unclear, although its association with extraglandular manifestations is relatively well accepted (6,26).…”

Section: Discussionmentioning

confidence: 99%

Clinical usefulness of anti-muscarinic type 3 receptor autoantibodies in patients with primary Sjögren's syndrome

Mona

Mondello

Hyon

et al. 2021

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

ObjectiveTo elucidate the clinical values of anti-M3R in Sjögren's syndrome (SS) in the largest cohort for an anti-M3R study. MethodsThe plasma of 361 subjects (156 primary SS [pSS], 62 non-SS-sicca [SICCA], 40 systemic lupus erythematosus [SLE], 50 rheumatoid arthritis [RA], and 53 healthy controls [HC]) was screened using our modified On-Cell-Western assay. Saliva from pSS (n=37) compared to SICCA (n=26) was also analysed. The sensitivity and specificity of anti-M3R and its association with comprehensive clinical and laboratory features were determined. ResultsPlasma-anti-M3R was higher in pSS compared to other groups, differentiating pSS with good-to-excellent diagnostic power with a specificity of 85% and a sensitivity between 75% and 98%. pSS plasma-anti-M3R was positively correlated with ocular staining scores, anti-Ro/SSA, IgG, β2-microglobulin, ESR, and ESSDAI. It was negatively correlated with WBC, C4, and salivary scintigraphic indices. Saliva-anti-M3R was 3.59 times higher in pSS than in SICCA. Interestingly, the agreement between the 2002 American European Consensus Group criteria and the criteria substituted with plasma-anti-M3R for the lip biopsy reached 92%, with a significant kappa of 0.824. ConclusionAnti-M3R enhances sensitivity and specificity for SS diagnosis, correlating with ocular dryness and glandular hypofunction, and the haematological/biological domains of the ESSDAI. Our findings also highlight the clinical significance of anti-M3R in SS diagnosis, especially where clinical assessments, such as lip biopsy, sialometry, or ocular evaluation, by multi-disciplinary specialists are limited.

show abstract

Handheld spatial frequency domain imager for noninvasive Sjögren's syndrome labial salivary gland biopsy

Zeng

Guo

et al. 2021

Biomed. Opt. Express

View full text Add to dashboard Cite

A labial salivary gland biopsy (LSGB) plays an essential role in diagnosing Sjögren's syndrome (SS), but its clinical application is limited due to its invasiveness. Here, we present a handheld single snapshot multiple-frequency demodulation-spatial frequency domain imaging (SSMD-SFDI) device for a rapid optical biopsy of labial salivary glands noninvasively. The structural and physiological parameters of lower lip mucosa were obtained from the light reflectance of the layered oral mucosa. The recovered parameters were found to correlate strongly with the progression of SS. In our pilot study on 15 healthy subjects and 183 SS patients, a support vector machine (SVM) classifier using the measured parameters distinguished healthy subjects, LSGB I, II, III, and IV patients in sequence with AUCs of 0.979, 0.898, 0.906, and 0.978, respectively. Critical structural and physiological alterations in the mucosa due to SS were further identified and used to assess its risk using an explainable neural network. The handheld spatial frequency domain imager may serve as a valuable label-free and noninvasive tool for early diagnosing and surveying SS.

show abstract

Efficient diagnosis of Sjögren's syndrome to reduce the burden on patients

Cited by 3 publications

References 15 publications

A Point-Scoring System for the Clinical Diagnosis of Sjögren's Syndrome Based on Quantified SPECT Imaging of Salivary Gland

A Point-Scoring System for the Clinical Diagnosis of Sjögren's Syndrome Based on Quantified SPECT Imaging of Salivary Gland

Clinical usefulness of anti-muscarinic type 3 receptor autoantibodies in patients with primary Sjögren's syndrome

Handheld spatial frequency domain imager for noninvasive Sjögren's syndrome labial salivary gland biopsy

Contact Info

Product

Resources

About